Aktieanalys

Lytix Q2 2024: Verrica’s Phase II Data Changes the Case - Redeye

{newsItem.title}

Redeye Publicerad: 29 Aug 13:47

Lytix Biopharma

Redeye comments on Lytix’ second quarter report 2024. Strong phase II data were presented by Verrica in August. This changes the investment case somewhat, putting basal cell carcinoma on an equal footing with melanoma.

Länk till analysen i sin helhet: https://www.redeye.se/research/1036610/lytix-q2-2024-verricas-phase-ii-data-changes-the-case?utm_source=finwire&utm_medium=RSS

Nyheter om Lytix Biopharma

Läses av andra just nu

Om aktien Lytix Biopharma

Senaste nytt